Pharmacokinetic & Dose Response Study of Asfotase Alfa in Adult Patients

See also
Status	Clinical Trial	Phase
Completed	`NCT03418389` - Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
Recruiting	`NCT02237625` - Natural History Study of Patients With Hypophosphatasia (HPP)
Completed	`NCT02291497` - Burden of Disease in Hypophosphatasia (HPP)	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Active, not recruiting	`NCT04195763` - Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
Not yet recruiting	`NCT05596539` - Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
Completed	`NCT02751801` - Health Burden of Hypophosphatasia
Completed	`NCT02796885` - Characterisation of Adult-Onset Hypophosphatasia
Completed	`NCT05890794` - Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia	Phase 1/Phase 2
Recruiting	`NCT06079359` - Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Phase 3
Recruiting	`NCT05234567` - A Prospective Sub-Study of the Global Hypophosphatasia Registry
Completed	`NCT01163149` - Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)	Phase 2
Completed	`NCT04925804` - Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)
Completed	`NCT02531867` - Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan	Phase 4
Completed	`NCT01406977` - Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)	Phase 2
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed	`NCT01176266` - Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)	Phase 2/Phase 3
Withdrawn	`NCT00894075` - Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)	Phase 2
Active, not recruiting	`NCT04222452` - The PORTRAIT Study
Recruiting	`NCT06079281` - Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa	Phase 3

NCT number	NCT02797821
Study type	Interventional
Source	Alexion Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	June 6, 2016
Completion date	June 21, 2017

Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms